Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases	Advanced Glioblastoma; MGMT-Unmethylated Glioblastoma; Metastatic Melanoma in the Central Nervous System	Recruiting	Phase 2	2025-07-22		NCT05909618

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Prof. Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel.	1
Sheba Medical Center	63

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Sheba medical center	Ramat Gan	Israel	2

Clinical trials